David Sinclair is probably the reason you've heard of NMN. The Harvard genetics professor has become the public face of longevity science — equal parts serious researcher and supplement celebrity. His work is genuinely impressive, but his public persona invites scrutiny. Here's what his research actually shows, what he personally takes every morning, and where the scientific community really stands on all of it.

Who Is David Sinclair?

David Sinclair grew up in Australia, earned his PhD in molecular genetics from the University of New South Wales in 1995, then crossed the Pacific to do postdoctoral work at MIT under Leonard Guarente — one of the scientists who first connected sirtuins to longevity. By 2000, he'd landed a faculty position at Harvard Medical School, where he's been ever since. Today he co-directs the Paul F. Glenn Center for Biology of Aging Research at Harvard, holds an Officer of the Order of Australia for his contributions to medical research, and was named one of TIME's 100 Most Influential People back in 2014.

That's a legitimate pedigree. Hundreds of peer-reviewed publications in Cell, Nature, Science — the journals that don't let you in without serious evidence. Whatever you think of his public persona, the man's science has passed through some of the toughest gatekeepers in academia.

His lab has spent over two decades pushing at the boundaries of what we understand about aging. The work falls into a few big buckets: sirtuin activation (his lab identified that resveratrol activates SIRT1, a key longevity gene), the role of declining NAD+ in age-related mitochondrial dysfunction, the "Information Theory of Aging" (we'll get to that), and cellular reprogramming — his team showed that partial reprogramming using Yamanaka factors could actually restore vision in aged mice, published in Nature in 2020.

That last one is worth pausing on. Restoring sight in old, glaucoma-damaged mice. That's not an incremental finding.

What Has Sinclair's Lab Published About NMN?

The Key Studies

Let's walk through the major papers, because the details matter.

In 2013, Sinclair's team published a landmark paper in Cell showing that NAD+ levels decline with age in mice and that raising NAD+ with NMN restored mitochondrial function in aged muscle tissue. The treated mice had metabolic profiles that looked like much younger animals. This was the paper that really established the mechanistic link between NAD+ decline and aging — it gave the field a concrete molecular target.

The following year (2014), his lab published in Cell Reports demonstrating that NMN promoted blood vessel growth in aged mice and improved blood flow. Essentially, vascular function got dialled back to more youthful levels. If you're thinking about why cardiovascular health deteriorates with age, this is a piece of the puzzle.

By 2018, research from the lab showed that NMN improved exercise endurance in older mice — the treated animals significantly outperformed untreated controls on a treadmill. For anyone who's noticed that exercise just gets harder with every passing decade, that's an intriguing result.

And then came the 2020 Nature paper on reversing aging in the eye. This is arguably Sinclair's most significant finding. His team used gene therapy (Yamanaka factors) to restore vision in aged mice with glaucoma. Now, this study used gene therapy rather than NMN directly, but NAD+ played a supporting role in the epigenetic reprogramming process. The bigger takeaway was the principle: age-related damage could potentially be reversed, not just slowed down.

What His Research Shows vs. What It Doesn't

Here's where we need to be honest — and where a lot of NMN marketing goes off the rails.

What the research clearly demonstrates:

• NAD+ decline is a hallmark of aging in mice
• NMN supplementation raises NAD+ levels and reverses some aging markers in mice
• The sirtuin pathway is a genuine mechanism linking NAD+ to longevity
• Epigenetic aging may be reversible (at least partially, in mice)

What hasn't been proven yet:

• Most of Sinclair's key findings are in mice, not humans
• Whether NMN extends human lifespan (this would take decades to study)
• Whether the dramatic mouse results translate proportionally to humans
• Whether his personal supplement protocol provides the benefits he describes

That gap between "exciting mouse data" and "proven human therapy" is real, and it's important. We think NMN is worth taking based on the totality of evidence, but we're not going to pretend the science is more settled than it is.

What Is David Sinclair's Personal NMN Protocol?

Sinclair has shared his personal supplement and lifestyle protocol pretty openly — in interviews, on podcasts, and in his 2019 book Lifespan. He's always careful to note that this is his personal choice and not a clinical recommendation. Fair enough. But people are understandably curious about what a Harvard aging researcher actually puts in his own body.

His Reported Daily Supplement Stack

His Lifestyle Practices

It's not just supplements. Sinclair has talked about several lifestyle habits:

• Intermittent fasting — He skips one meal per day (typically breakfast), aiming for time-restricted eating
• Exercise — Regular physical activity, though he's candidly admitted he could exercise more (relatable, honestly)
• Cold exposure — Occasional cold exposure for metabolic activation
• Stress management — Staying mentally engaged and purposeful
• Diet — Plant-heavy, limits red meat, avoids sugar

Important Caveats About His Protocol

Before you rush to copy this stack, a few things you should know:

First, no clinical trial has ever tested this specific combination. We have data on individual components, but the whole package together? That's Sinclair's personal experiment, not validated science.

Second, metformin is prescription-only. Sinclair takes it off-label for longevity purposes. You can't — and shouldn't — just order it online without a doctor's involvement.

Third, and this is crucial: it's an N=1 experiment. One person's supplement regimen, no matter how well-credentialed that person is, doesn't constitute scientific evidence. Sinclair himself has explicitly stated that his protocol is not medical advice.

And fourth — Sinclair co-founded Metro International Biotech, a company developing NMN-based therapeutics, and holds financial interests in the longevity supplement space. That doesn't mean he's lying about his protocol, but it's context you should have.

The "Information Theory of Aging" — Sinclair's Big Idea

This is where Sinclair goes from "accomplished researcher" to "someone trying to change how we think about aging entirely."

The Core Idea

Sinclair proposes that aging is primarily caused by the loss of epigenetic information — the instructions that tell your cells which genes to turn on and off. Think of your DNA as a hard drive full of data, and the epigenome as the software that decides which files to open. Over a lifetime, as cells respond to DNA damage, stress, and environmental insults, that software gets corrupted. A skin cell starts behaving less like a skin cell. A liver cell becomes less efficient at liver functions. The data is still there — it's the reading of the data that breaks down.

It's an elegant theory. It's also a hopeful one, because if aging is an information problem rather than a hardware problem, it might be fixable.

Why This Matters for NMN

NAD+ sits right at the centre of this theory:

1. Sirtuins (which require NAD+ to function) are key regulators of epigenetic maintenance
2. When NAD+ levels drop with age, sirtuins can't do their job of keeping the epigenome intact
3. Restoring NAD+ through NMN theoretically gives sirtuins the fuel they need to maintain epigenetic integrity
4. Sinclair's mouse experiments suggest this process may be at least partially reversible

In other words: if the theory is right, NMN isn't just a generic "anti-aging" supplement — it's addressing one of the root causes of why we age in the first place.

Scientific Reception

Not everyone buys it. The Information Theory of Aging is not universally accepted, and that's fine — science is supposed to be argumentative.

While the role of epigenetic changes in aging is well-established, some researchers push back on making it the central cause. Aging is complicated. Multiple mechanisms — telomere shortening, mitochondrial dysfunction, cellular senescence, chronic inflammation — probably all contribute simultaneously. And the evidence for full reversibility remains limited to specific tissues in mice.

That said, most aging researchers agree that epigenetic dysregulation is a significant component of aging, and that NAD+ clearly plays a role in epigenetic maintenance. The debate is really about how much of the aging picture this explains, not whether it's part of the picture.

Criticism and Controversy

Here's where we need to talk about the uncomfortable stuff. If we're going to take Sinclair seriously — and we think we should — we also need to take the criticism seriously.

Scientific Criticism

The most common pushback from fellow researchers falls into a few categories:

Mouse-to-human extrapolation is the big one. Many interventions that work brilliantly in mice fail completely in humans. Mice have fundamentally different metabolic rates, lifespans, and disease susceptibilities. The history of medical research is littered with "cured it in mice" announcements that went nowhere in people.

Overpromising is another concern. Some scientists feel Sinclair's public statements — on podcasts, in interviews, on social media — imply greater certainty about human benefits than the published evidence supports. There's a difference between "this is extremely promising preclinical data" and "we can reverse aging," and critics argue Sinclair sometimes blurs that line.

Replication questions have also come up. Some of his sirtuin-related findings from the 2000s have been debated regarding replicability, particularly around how exactly resveratrol activates SIRT1.

Commercial Conflicts of Interest

This is the part that makes scientists uncomfortable, and it should make you think carefully too:

• Sinclair co-founded Metro International Biotech to develop NMN-based therapeutics
• He serves as an advisor to InsideTracker, a biomarker testing company
• He holds multiple advisory roles and equity stakes in longevity-related companies
• His public advocacy for NMN directly overlaps with his commercial interests

Here's our balanced take on this: Financial conflicts don't automatically invalidate research. If they did, we'd have to throw out half of modern biomedical science. Sinclair publishes in peer-reviewed journals where his work undergoes independent scrutiny, and many of his core findings have been replicated by independent labs around the world. The science stands or falls on its own merits, not on who funded it.

But — and this is a big but — his public advocacy does go beyond what the published research strictly supports. When a researcher who stands to profit from NMN sales tells you NMN is life-changing, you should weigh that statement differently than you'd weigh the same claim from someone with no financial stake. This isn't cynicism. It's just good critical thinking.

The FDA and Metro International Biotech

In 2022, things got messy. The FDA determined that NMN could not be marketed as a dietary supplement because Metro International Biotech (Sinclair's company) had filed an Investigational New Drug (IND) application for NMN. The move was controversial for several reasons:

• It potentially removed a widely-used supplement from the market
• Critics argued that Sinclair's company was effectively trying to monopolise NMN through the pharmaceutical pathway
• Sinclair distanced himself from the FDA's decision
• In practice, enforcement has been minimal, and NMN remains widely available

Whether this was a legitimate regulatory process or a calculated business strategy depends on who you ask. Either way, it didn't exactly help Sinclair's credibility with people who were already sceptical of his commercial entanglements.

Where Does the Scientific Consensus Stand on NMN?

Let's step back from Sinclair the person and look at where the broader research community actually lands.

What Most Aging Researchers Agree On

1. NAD+ declines with age — This is well-established and not controversial
2. NMN effectively raises NAD+ levels in humans — Confirmed by multiple randomised controlled trials
3. Sirtuins require NAD+ — The biochemistry is clear and uncontested
4. NMN is safe at tested doses — No serious adverse effects in human trials to date

What Remains Debated

1. How much human benefit NMN actually provides — Mouse results may not translate proportionally
2. Whether NMN extends human lifespan — We simply can't test this in any reasonable timeframe
3. Optimal dosing and duration — Still being refined through ongoing trials
4. Whether the cost-benefit ratio justifies supplementation — Some argue the evidence isn't strong enough yet to recommend widespread use

The Pragmatic View

If you pushed most researchers to give you a straight answer, you'd probably get something like this: "NMN is a biologically plausible supplement with a strong safety profile that reliably raises NAD+ levels. The preclinical evidence is exciting. The human evidence is early but encouraging. Whether the dramatic mouse results translate to meaningful human benefits remains the key open question."

We think that's about right. And we think that for people who want to act on the best available evidence rather than wait another 20 years for definitive proof, NMN is a reasonable bet — as long as you go in with realistic expectations.

Key Takeaways From Sinclair's Work

1. NAD+ decline is a real driver of aging — Not the only one, but a significant one with solid evidence behind it
2. NMN is the most direct way to raise NAD+ — This is well-supported by the biochemistry and human trial data
3. The combination of NMN + resveratrol has scientific logic — Fuel for the sirtuins plus an activator to get them working
4. Human evidence is growing but not yet definitive — We're still in the early innings of human longevity research
5. Sinclair's personal protocol is interesting but unproven — It's one man's experiment, informed by deep expertise but still just N=1
6. Commercial interests exist and matter — Factor them in, but don't dismiss the underlying science because of them

The Dan Alchemy Approach

Sinclair's research on the sirtuin-NAD+ axis is a big part of what informed our NAD+ Elixir formulation. We built it around the same core principle — provide both the fuel (NMN) and the activator (resveratrol) to support the sirtuin pathway:

• 500 mg NMN — Pharmaceutical-grade, 99.5%+ purity
• Trans-resveratrol — SIRT1 activation
• TMG — Methylation support (same reason Sinclair includes it in his own stack)
• Black pepper extract — Enhanced bioavailability

We believe in the science behind the NAD+ pathway. We also believe in being straight with you — which means acknowledging what the research shows, what looks promising, and what still needs to be proven.

Explore the NAD+ Elixir →

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.